Ceruloplasmin is an endogenous inhibitor of myeloperoxidase by Chapman, Anna L. P. et al.
Ceruloplasmin Is an Endogenous Inhibitor of
Myeloperoxidase*
Received for publication, September 12, 2012, and in revised form, January 9, 2013 Published, JBC Papers in Press, January 10, 2013, DOI 10.1074/jbc.M112.418970
Anna L. P. Chapman‡, Tessa J. Mocatta‡, Sruti Shiva§, Antonia Seidel¶1, Brian Chen‡, Irada Khalilova‡,
Martina E. Paumann-Page‡, Guy N. L. Jameson¶, Christine C. Winterbourn‡, and Anthony J. Kettle‡2
From the ‡Centre for Free Radical Research, Department of Pathology, University of Otago, Christchurch, Christchurch 8140,
New Zealand, the ¶Department of Chemistry, University of Otago, PO Box 56 Dunedin, New Zealand, and the §Vascular Medicine
Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
Background:Myeloperoxidase promotes oxidative stress during inflammation by producing hypochlorous acid.
Results: Ceruloplasmin was a potent inhibitor of myeloperoxidase and slowed its activity in plasma from wild type mice
compared with ceruloplasmin knock-out animals.
Conclusion: Ceruloplasmin is a physiologically relevant inhibitor of myeloperoxidase.
Significance: Ceruloplasmin will provide a protective shield against oxidant production by myeloperoxidase during
inflammation.
Myeloperoxidase is a neutrophil enzyme that promotes oxi-
dative stress in numerous inflammatory pathologies. It uses
hydrogenperoxide to catalyze the production of strong oxidants
including chlorine bleach and free radicals. A physiological
defense against the inappropriate action of this enzyme has yet
to be identified. We found that myeloperoxidase oxidized 75%
of the ascorbate in plasma from ceruloplasmin knock-out mice,
but there was no significant loss in plasma from wild type ani-
mals. When myeloperoxidase was added to human plasma it
became bound to other proteins and was reversibly inhibited.
Ceruloplasmin was the predominant protein associated with
myeloperoxidase. When the purified proteins were mixed, they
became strongly but reversibly associated. Ceruloplasmin was a
potent inhibitor of purified myeloperoxidase, inhibiting pro-
duction of hypochlorous acid by 50% at 25 nM. Ceruloplasmin
rapidly reduced Compound I, the FeV redox intermediate of
myeloperoxidase, to Compound II, which has FeIV in its heme
prosthetic groups. It also prevented the fast reduction of Com-
pound II by tyrosine. In the presence of chloride and hydrogen
peroxide, ceruloplasmin converted myeloperoxidase to Com-
pound II and slowed its conversion back to the ferric enzyme.
Collectively, our results indicate that ceruloplasmin inhibits
myeloperoxidase by reducing Compound I and then trapping
the enzyme as inactive Compound II. We propose that cerulo-
plasmin should provide a protective shield against inadvertent
oxidant production by myeloperoxidase during inflammation.
Myeloperoxidase is a promiscuous neutrophil enzyme that
generates hypohalous acids and free radicals (1, 2). It is pack-
aged in the azurophilic granules of neutrophils and released
into phagosomes when they ingest and kill bacteria (3). The
oxidants it generates provide a front-line defense against
phagocytosed pathogens (4). Myeloperoxidase is also released
into the extracellular space as a result of incomplete phagosome
closure and during chronic inflammation when neutrophils
are activated and degranulate in the absence of infection. In
these situations, its oxidants have considerable potential to
damage host tissue and are linked to numerous inflammatory
diseases. Elevated levels of myeloperoxidase have been meas-
ured in all stages of heart disease (5) and track with major
adverse cardiac events (6, 7). There are implications for the
negative involvement of myeloperoxidase in cystic fibrosis,
chronic obstructive pulmonary disease, rheumatoid arthritis,
and Alzheimer disease (2, 8). Hypochlorous acid, the enzyme’s
major product, is a strong oxidant that reacts with proteins,
lipids, and DNA (2). It oxidizes thiols in cells to promote apo-
ptosis and necrosis at high and low doses, respectively (9, 10).
Its chlorination footprint, 3-chlorotyosine, has been detected in
proteins from inflammatory foci (8, 11, 12). The tumor suppres-
sor protein p53 is exquisitely sensitive to hypochlorous acid and
chloramines (13). Protein carbamylation, via myeloperoxidase-
derived hypothiocyanous acid, is a mechanism that has been
proposed to link inflammation, smoking, uremia, and coronary
artery disease pathogenesis (14).Whenmyeloperoxidase reacts
with hydrogen peroxide it forms a redox intermediate called
Compound I, which contains FeV in its heme prosthetic groups.
Compound I is reduced via one electron to form Compound II,
which is an FeIV intermediate. Myeloperoxidase generates
damaging radicals when these redox intermediates oxidize
tyrosine, urate, and myriad xenobiotics (2, 15, 16). The radicals
promote chain reactions or couple with superoxide to form
reactive hydroperoxides (17, 18).
Given the substantial potential of myeloperoxidase to exac-
erbate the oxidative stress associated with inflammation, it
raises the question as towhether an endogenous inhibitor exists
to limit its activity in the extracellular environment of neutro-
phils. As an analogy, 1-antitrypsin provides an important
shield against the proteolysis elicited by neutrophil elastase,
which is discharged along with myeloperoxidase when these
inflammatory cells are stimulated (19).
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The plasma protein ceruloplasmin is a possible candidate for
a physiological inhibitor of myeloperoxidase. It is an abundant
acute phase protein that has been demonstrated to interact
with myeloperoxidase in plasma (20, 21). Ceruloplasmin binds
to myeloperoxidase with a binding constant of 7.5  106 M1
(22). It has been proposed that there is an electrostatic interac-
tion between the two proteins due to the cationic nature of
myeloperoxidase (pI 10) and anionic charges on ceruloplas-
min (pI4) (20).
Ceruloplasmin was first demonstrated to prevent hypo-
chlorous acid-dependent inactivation of 1-anti-protease by
myeloperoxidase (23). In subsequent studies, it was found to be
a modest inhibitor of the halogenation activity of myeloperoxi-
dase (24, 25). Ceruloplasmin was also shown to inhibit the per-
oxidase activity of myeloperoxidase (20, 22), but there were
inconsistencies in the extent of inhibition, with values for inhi-
bition ranging from 40 to 70%. The degree of inhibition also
increased with increasing size of the peroxidase substrate (25).
This suggested that binding of ceruloplasmin to myeloperoxi-
dase hinders large substrates from accessing the active site of
the enzyme. As a corollary, this result implies that ceruloplas-
min is unlikely to be an effective inhibitor of the oxidation of
either chloride or thiocyanate, which are small anions.
As a result of these variable findings, ceruloplasmin has
largely been ignored as a potentially important inhibitor of
myeloperoxidase. Currently, there is no evidence to support
ceruloplasmin functioning as an inhibitor of myeloperoxidase
in vivo, and the mechanism of inhibition has yet to be conclu-
sively determined. In the present study, we sought evidence for
effective inhibition of myeloperoxidase by ceruloplasmin in
blood plasma and aimed to clarify themechanism bywhich this
occurs. We show that myeloperoxidase is more active in pro-
moting the oxidation of ascorbate in the plasma of ceruloplas-
min knock-out mice than in wild type animals, suggesting that
ceruloplasmin will attenuate the production of hypochlorous
acid in vivo. Furthermore, using appropriate assays, we show
that ceruloplasmin is a potent inhibitor of hypochlorous acid
production.
EXPERIMENTAL PROCEDURES
Materials—Purified myeloperoxidase was purchased from
Planta (Austria). Its concentrationwas calculated from its heme
absorbance (430  89,000 M1 cm1/heme). All concentra-
tions are given per heme, so that the protein concentration of
myeloperoxidase was always half this value. Hypochlorous acid
(Sarah Lee, Auckland, New Zealand) concentrations were
determined from its absorbance at 292 nm (pH 12, 292  350
M1 cm1) (26). Antibodies to myeloperoxidase and cerulo-
plasmin were from Abcam (Cambridge, UK), and goat anti-
rabbit immunoglobulin biotin conjugate secondary antibodies
were fromDako (Campbellfield, Australia). All other chemicals
were purchased from either Sigma or BDH (Poole, UK).
Ceruloplasmin Knock-out Mice—Wild type (Cp/)3 and
homozygous ceruloplasmin knock-out (Cp/) mice (males
and females)were originally a kind gift fromDr. Z. L.Harris and
bred at theUniversity of Pittsburgh. Themice are on aC57/BL6
background and back-crossed more than 12 generations. They
were allowed food and water ad libitum and were kept on a
12-h/12-h light/dark cycle. All animal procedures were
approved by the Institutional Care and Use Committee of the
University of Pittsburgh. Blood was taken from the mice into
heparin-containing tubes (100 units/ml units), as described
previously (27). Plasma ceruloplasmin ferroxidase activity was
measured in the knockouts and found to be 5% of the wild
types.
Measurement of Ascorbate Oxidation in Plasma from Ceru-
loplasmin KOMice by HPLC—Plasma from Cp/ and Cp/
mice (50l) was incubatedwithmyeloperoxidase (25 nM) for 15
min prior to the addition of glucose oxidase (generating 5
M/min hydrogen peroxide as measured by the Fox assay (28)).
Ascorbate levels in the plasma were checked, and because all
ascorbate had been lost during storage, 50 M was added to all
samples with the myeloperoxidase. Reactions were stopped
after 5min by the addition of an equal volume of perchloric acid
(0.54 M) to precipitate proteins. Precipitated proteins were pel-
leted, and the supernatants were assayed for ascorbate by
reverse-phaseHPLC on a Synergi 4-mcolumn (Phenomenex)
with electrochemical detection (29).
Isolation of Ceruloplasmin from Plasma—Protein from
pooled plasma (1.4 liter from healthy volunteers) was sequen-
tially precipitated with 30 and 55% ammonium sulfate. The
second precipitate was dissolved in deionized water and then
dialyzed against sodium acetate buffer (50 mM, pH 5) prior to
separation onDEAE-Sephadex at 4 °C. Protein was eluted from
the column via a linear gradient from pH 5 to pH 4 using 50mM
sodium acetate containing 0.4 M NaCl. Fractions with absorb-
ance at 610 nm (due to copper in ceruloplasmin) were pooled,
and protein was precipitated as described above. Precipitated
protein was dissolved in sodium acetate buffer (25 mM, pH 5,
containing 1 M ammonium sulfate (buffer A)) and applied to a
phenyl-Sepharose column. A stepwise elution of proteins was
carried out as follows; 100% A, 75% A, and 25% B (sodium ace-
tate buffer (25 mM), pH 5), 50% A and 50% B, 25% A and 75% B,
and 100% B. Fractions with absorbance at 610 nmwere pooled,
dialyzed against deionizedwater, and freeze-dried. The purified
protein had a purity index of 0.042 (A610/A280) and was 80%
pure. This is based on the purity index for pure ceruloplasmin
of 0.052 (20). The protein was recognized by commercial anti-
bodies to ceruloplasmin.
High Performance Size Exclusion Chromatography—My-
eloperoxidase (30g, 6.8M), ceruloplasmin (30–150g, 3.9–
19.5 M), and mixtures of the two proteins were incubated in
phosphate buffer (0.1 M, pH 7, containing 0.1 M NaCl) for 1 h
prior to separation on an Alltech ProSphere 250 5-m size
exclusion column (7.8 300mm). Themobile phase was phos-
phate buffer (0.1 M, pH 7, containing 0.1 M NaCl), with a flow
rate of 0.5 ml/min and detection at 280, 430, and 610 nm. The
column was calibrated with the following protein standards:
ferritin (440 kDa), bovine serum albumin (66 kDa), and horse-
radish peroxidase (44 kDa), which eluted at volumes of 6.8, 8.1,
and 9 ml, respectively. When myeloperoxidase was separated
from plasma proteins, its activity was monitored in fractions
3 The abbreviations used are: Cp/, ceruloplasmin wild type mice; Cp/,
ceruloplasmin knockoutmice; TMB, 3,3,5,5-tetramethylbenzidine; CTAC,
cetyltrimethylammonium chloride; DTPA, diethylenetriaminepentaacetic
acid.
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using 3,3,5,5-tetramethylbenzidine (TMB) as a reducing sub-
strate as described previously (26). The accumulation of blue
product was detected at 650-nm oxidation over a 15-min incu-
bation period.
Immunoprecipitation of Myeloperoxidase from Plasma—
EDTA anti-coagulated plasma from a healthy donor was added
to myeloperoxidase (100 nM) and incubated at room tempera-
ture with end over end mixing for three hours. Plasma alone
was used as a control. Polyclonal anti-myeloperoxidase anti-
body was covalently bound to Protein G-Dynabeads following
the manufacturer’s instructions. 0.1% IPEGAL (octylphenyl-
polyethylene glycol) was added to the plasma sample, followed
by the beads. The sample was incubated at 4 °C with end over
end rotation for 18 h. The beads were collected using a magnet
and washed five times in phosphate-buffered saline (PBS; 10
mM phosphate and 140 mM Cl) containing 0.1% IPEGAL.
Bound proteins were eluted with 0.1 M glycine, pH 3. The pH of
the eluant was neutralized, and proteins were precipitated
using 20% (v/v) trichloroacetic acid, 20% (v/v) acetone, 0.1%
(w/v) sodium deoxycholate. Air-dried precipitates were resus-
pended in reducing SDS-PAGE loading buffer (2% (w/v) SDS,
10% (v/v) glycerol, 125 mM Tris-HCl buffer, pH 6.5, 1% (v/v)
-mercaptoethanol).
Simultaneous Detection of Myeloperoxidase Activity and
Myeloperoxidase Protein by an ELISA—Interactions between
myeloperoxidase and ceruloplasmin were investigated using a
sandwich ELISA. In this assay, a standard curve was prepared
with purifiedmyeloperoxidase and used to determine the activ-
ity and protein levels in samples. Myeloperoxidase in buffer or
10-fold diluted plasma was captured by a monoclonal anti-my-
eloperoxidase antibody. Its enzyme activity was detected by
adding hydrogen peroxide (20 M) to Amplex Red (50 M) in a
50 mM phosphate buffer, pH 7.4, containing 50 mM NaBr. The
plate was subsequently washed to remove peroxidase sub-
strates and products. Myeloperoxidase protein was then
probed using rabbit polyclonal anti-myeloperoxidase antibody
coupled to goat anti-rabbit immunoglobulin-biotin conjugate
and detected with an avidin-alkaline phosphatase conjugate
and p-nitrophenyl phosphate. To determine whether cerulo-
plasmin became bound to myeloperoxidase, mixtures of the
two proteins were applied to the plate, and myeloperoxidase
was captured as described above. The plate was washed thor-
oughly, and ceruloplasmin was then detected using a poly-
clonal antibody to ceruloplasmin as described above for
myeloperoxidase.
Measurement of Hypohalous Acid Production—Formation of
hypochlorous acid was measured in a discontinuous assay by
capturing it with taurine and then detecting accumulated tau-
rine chloramine (30). Myeloperoxidase (20 nM) was incubated
in the presence or absence of ceruloplasmin (100 nM) and tau-
rine (5 mM) in 10 mM phosphate buffer, pH 7.4, containing 140
mM sodium chloride (PBS) and diethylene triamine pentaacetic
acid (DTPA, 100M) for 5–60min.Hydrogen peroxide (50M)
was added to start the reaction. After sufficient time to con-
sume 50% of the hydrogen peroxide (3–10 min), reactions
were stopped by the addition of catalase (32g/ml), and taurine
chloramine was quantified by measuring the oxidation TMB in
the presence of iodide.
Production of hypochlorous acidwas alsomeasured in a con-
tinuous assay bymonitoring the oxidation of ascorbate at 265.5
nm (265  15,000 M1 cm1) (31). Reactions were started by
the addition of a bolus of hydrogen peroxide (50 M) to a solu-
tion containing myeloperoxidase (20 nM), cetyltrimethylam-
monium chloride (CTAC, 0.01%), and ascorbate (100 M) in
PBS with DTPA (100 M) plus or minus ceruloplasmin. Initial
rates were determined over the first 30 s of the reaction. In
experiments in which the concentration of chloride was varied,
isotonicity was kept constant by the addition of Na2SO4.
The halogenation ofNADHwas also used as ameasure of the
rate of hypochlorous or hypobromous acid production by
myeloperoxidase (32). Myeloperoxidase was incubated with
ceruloplasmin as described above, in the presence of NADH
(100 M) and either chloride (140 mM) or bromide (1 mM).
Hydrogen peroxide (50M) was added to start hypohalous acid
production, and the initial rate of NADH chlorohydrin or bro-
mohydrin formation was determined over the first 30 s of the
reaction by monitoring the increase in absorbance at 275 nm
(275 11,000 M1 cm1) (33).
Measurement of Peroxidase Activity—Myeloperoxidase (5
nM) was incubated with serotonin (0–1 mM) with or without
ceruloplasmin (100 nM) for 1 h at room temperature in 50 mM
phosphate buffer, pH 7.4, containing DTPA (100 M) and
CETAC (0.01%). Reactions were started by the addition of a
bolus of hydrogen peroxide (50 M), and the rate of serotonin
dimer formation was monitored at 317 nm (34).
SDS-PAGE—Myeloperoxidase (5 M) was incubated in PBS
with or without ceruloplasmin (5 M) for 1 h at room temper-
ature. When used, hydrogen peroxide (50 M) was added for 3
min prior to the addition of SDS-PAGE non-reducing loading
buffer (62.5 mM Tris, pH 6.8, 20% (v/v) glycerol, 2% (v/v) SDS,
0.5% (w/v) bromphenol blue). Sampleswere loaded onto 7.5%T
acrylamide gels. Gels were stained with Coomassie Blue G-250.
In immunoprecipitation experiments, samples were resolved
on 8% SDS-polyacrylamide gels under reducing conditions and
silver-stained. New protein bands were excised, analyzed, and
identified by mass spectrometry. All gels were run at 200 V
constant for50 min.
Mass Spectrometry—SDS-PAGE protein bands were sub-
jected to in-gel digestionwith trypsin (35). Eluted peptideswere
dried and resolubilized in 5% (v/v) acetonitrile, 0.2% (v/v) for-
mic acid. Samples were injected onto an Ultimate 3000 nano-
flow ultra-HPLC system (Dionex Co.) coupled to an LTQ-Or-
bitrap XL hybrid mass spectrometer (Thermo Scientific, San
Jose, CA). Peptideswere separated on an in-house packed emit-
ter tip C-18 column at 200–500 nl/min by a gradient from 5 to
80% acetonitrile, both in 0.2% (v/v) formic acid. Themass range
was scanned betweenm/z 300 and 2000. For protein identifica-
tion, MS/MS data were searched against the HumanRefSeq 2
(38,753 sequences; 18,818,966 residues) database using the
Mascot search engine (see the Matrix Science Web site).
Spectral Analysis of Myeloperoxidase—An Agilent spectro-
photometer was used to record spectra of myeloperoxidase (1
M) between 350 and 700 nm at 15-s intervals after the addition
of hydrogen peroxide (100 M). Reactions were performed in
PBS with methionine (1 mM) added to scavenge hypochlorous
Ceruloplasmin Inhibits Myeloperoxidase
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acid. When added, ceruloplasmin or human serum albumin
was present at 10 M.
Stopped Flow Kinetics—Single turnover kinetics were meas-
ured on an SX-20MV stopped flow spectrometer (Applied Pho-
tophysics Ltd., Leatherhead, UK), using either a photomulti-
plier to follow single wavelengths or a photodiode array to
follow spectral changes. The temperature was maintained at
25 °C using a Haakemodel DC10-K10 refrigerated water circu-
lator thermostat. All kinetic measurements were carried out at
pH 7.4 using 50 mM phosphate buffer. In single mixing experi-
ments, myeloperoxidase (1.0 M final) with or without cerulo-
plasmin (1 M final) was reacted with hydrogen peroxide (10
M final), and the formation and decay of Compound I and
Compound II were followed. Sequential mixing experiments
allowed the reaction of Compound II with an external reduc-
tant to be studied.Myeloperoxidase (1.0M final) with or with-
out ceruloplasmin (1 M final) was premixed with hydrogen
peroxide (10 M final) and then reacted with tyrosine (200 M
final) after complete conversion of myeloperoxidase into Com-
pound II (20 s for enzyme alone and 2 s in the presence of
ceruloplasmin). Data were analyzed using Pro-Data Viewer
software (Applied Photophysics Ltd.) and Prism (GraphPad, La
Jolla, CA).
Statistics—To determine whether there were differences in
the extent of ascorbate oxidation by myeloperoxidase in the
plasma from wild type and Cp/ mice, a one-way analysis of
variance was performed (SigmaStat, Jandel Scientific, San
Rafael, CA). Wilcoxon’s paired signed rank test was used to
determine whether there was a significant difference between
the concentration of myeloperoxidase protein and its activity
when the enzyme was added to human plasma.
RESULTS
Ceruloplasmin Inhibits Myeloperoxidase in Plasma from
Mice—We first sought evidence that inhibition ofmyeloperoxi-
dase is a physiologically relevant function of ceruloplasmin by
comparing the oxidation of ascorbate in plasma from either
wild type (Cp/) mice or those deficient in ceruloplasmin
(Cp/). Plasma was supplemented with ascorbate so that its
initial concentration was 50 M. The addition of myeloperoxi-
dase alone to plasma had no effect on ascorbate concentrations
(Fig. 1). Glucose oxidase was also added to plasma so that it
generated a flux of hydrogen peroxide at a rate of5 M/min.
This promoted a small decrease in the concentration of ascor-
bate, which was similar in wild type and ceruloplasmin knock-
out mice. When myeloperoxidase and glucose oxidase were
added in combination, 75% (p  0.001) of the ascorbate was
oxidized in plasma from the Cp/ animals, whereas there was
no significant loss in the plasma from wild type mice. This
result demonstrates that the presence of ceruloplasmin in
plasma is associated with a substantial decrease in the ability of
myeloperoxidase to promote the oxidation of ascorbate.
Proteins in Human Plasma Bind Reversibly to Myeloperoxi-
dase and Inhibit Its Activity—To seek evidence that ceruloplas-
min inhibits myeloperoxidase in human plasma by becoming
associated with it, purified myeloperoxidase was added to
plasma, which was then fractioned by size exclusion chroma-
tography. Fractions were analyzed for peroxidase activity (Fig.
2A). In the absence of addedmyeloperoxidase, little peroxidase
activity was detected in plasma. Upon adding the enzyme to
plasma, twomajor peaks of activity were eluted with 7.7 and 8.7
ml of running buffer (Fig. 2A). The later peak eluted at the same
volume observed when myeloperoxidase alone was passed
through the column (Fig. 2B). Thus, the presence of an earlier
eluting peroxidase-positive peak indicates that myeloperoxi-
dase becomes associated with proteins in plasma. This earlier
peak had the same elution volume as that for a combination of
ceruloplasmin and myeloperoxidase (Fig. 2B). This result sug-
gests that myeloperoxidase may bind to ceruloplasmin in
plasma.
Next an ELISA was used to measure both the protein con-
centration of myeloperoxidase and its activity when the puri-
fied enzymewas added to human plasma.When 60 ng/ml 100%
activemyeloperoxidasewas added to plasma, its additional pro-
tein concentrationwas fully accounted for (Fig. 2C). In contrast,
less than half of the added enzyme activity could be detected.
This result indicated that when myeloperoxidase is added to
plasma, its specific activity is decreased. To understand the
nature of this inhibition, we added increasing concentrations of
fully active myeloperoxidase to plasma. As shown in Fig. 2D,
this resulted in increasing detection of enzyme activity in
plasma, but less than 20% of the added activity could be
detected. However, when the enzyme was extracted from the
plasma using cation exchange chromatography, most of its
activity was recovered. In comparison, most of the added
myeloperoxidase protein was detected before and after ion
exchange chromatography (Fig. 2E). Based on these results, we
conclude that proteins in plasma bind reversibly to myeloper-
oxidase and inhibit its activity.
To identify the proteins in plasma that myeloperoxidase
becomes associated with, the enzyme was added to plasma and
immunoprecipitated with a polyclonal antibody to myeloper-
oxidase. Co-precipitated proteins were resolved by SDS-PAGE
under reducing conditions (Fig. 2F). The dominant protein
band in the plasma sample containing myeloperoxidase had a
molecular mass of 130,000 Da and was identified by mass
FIGURE 1. Ceruloplasmin inhibits myeloperoxidase in murine plasma.
Plasma from Cp/ (black bars) and Cp/ (gray bars) mice (50 l) was incu-
bated with myeloperoxidase (MPO) (25 nM) for 15 min at 37 °C. Glucose oxi-
dase (GO), generating5 M/min hydrogen peroxide, was added, and sam-
ples were incubated for a further 5 min. Ascorbate levels were measured in
the plasma byHPLC. Data are themeans and S.E. (error bars) of three and four
replicates for Cp/ and Cp/ mice, respectively. Significant differences
(p 0.05) were determined by one-way analysis of variance.
Ceruloplasmin Inhibits Myeloperoxidase
6468 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 9•MARCH 1, 2013
 by guest on Septem
ber 17, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
spectrometry to be ceruloplasmin (Table 1). Minor bands that
were immunoprecipitated from the plasma were identified as
subunits of complement C3 as previously reported (20).
Ceruloplasmin Associates withMyeloperoxidase and Inhibits
Its Halogenation Activity—Size exclusion chromatography was
used to determine the likely stoichiometry of binding between
myeloperoxidase and ceruloplasmin. Myeloperoxidase has a
distinct absorbance at 430 nm due to its heme groups, whereas
the copper in ceruloplasmin absorbs at 610 nm. When passed
through the size exclusion column separately,myeloperoxidase
(146 kDa) and ceruloplasmin (132 kDa) eluted with retention
volumes of 8.8 and 7.9ml, respectively. An adduct of myeloper-
oxidase and ceruloplasmin was seen when the proteins were
incubated together at a ratio of 1:1. It eluted earlier (7.2ml), had
an approximate molecular mass of 280 kDa, and had absorb-
ance maxima at 430 and 610 nm (Fig. 3A). Increasing the ratio
of ceruloplasmin to myeloperoxidase to 2:1 (Fig. 3B) then 5:1
(Fig. 3C) caused a decrease in the peak for free myeloperoxi-
dase. It also promoted the formation of another highmolecular
weight adduct that eluted at 6.9 ml and absorbed at both 430
and 610 nm. These results indicate that myeloperoxidase and
ceruloplasmin form adducts with one another. They also sug-
gest that two molecules of ceruloplasmin become associated
with a single molecule of myeloperoxidase. Using SDS-PAGE,
we found thatmyeloperoxidase and ceruloplasminweremostly
reversibly associated but did form a minor reducible complex
(data not shown). This complex could not account either for the
association of the proteins observed by gel filtration or the inhi-
bition of peroxidase activity in plasma.
We then sought to provide evidence that association of the
proteins results in inhibition of myeloperoxidase. Mixtures of
the two proteins at physiologically relevant concentrations
were applied to an ELISA plate coated with a monoclonal anti-
myeloperoxidase antibody and then probed using an anti-ceru-
loplasmin polyclonal antibody. The amount of detectable ceru-
loplasmin on the plate increased with increasing ratios of
ceruloplasmin to myeloperoxidase, although it did not reach a
saturated level even when ceruloplasmin was present at a 1000-
fold excess (Fig. 4A). Mixtures of the proteins containing
increasing concentrations of myeloperoxidase and a 1000-fold
excess of ceruloplasmin were also added to an ELISA plate,
washed, and assayed for bound ceruloplasmin. The detection of
FIGURE 2. Associations of myeloperoxidase and with proteins in human
plasma. A, myeloperoxidase (MPO; 5 M) was incubated in heparinized
plasma (11 l) for 1 h at room temperature and then diluted 10-fold prior to
separation by size exclusion chromatography. Fractions were collected and
assayed forperoxidase activity usingTMBas the reducing substrate andmon-
itoring the increase in absorbance at 650 nmover 15min.E, plasma alone;F,
plasma and myeloperoxidase. B, protein fractions from the separation of
myeloperoxidase (30 g, 6.8 M) (F), ceruloplasmin (30 g, 3.9 M) (), or a
mixture of the two proteins (E) were passed through a size exclusion chro-
matography column and assayed for peroxidase activity. C, fully active
myeloperoxidase (60 ng/ml) was added to plasma from 10 healthy controls.
Myeloperoxidase protein concentration and activityweremeasuredby ELISA
before (open bars) and after adding the enzyme to the plasma (shaded bars).
Values were determined from a standard curve prepared using purified
myeloperoxidase. Therewas a significant differencebetween theprotein and
enzyme activity in the plasma with added myeloperoxidase (p  0.002).
Myeloperoxidase was added to plasma, and its activity (D) and protein con-
centration (E) were measured by an ELISA before (E) and after (F) extracting
the enzyme by cation exchange chromatography. Data are means and S.D.
(error bars) of triplicate measurements. F, plasma added to myeloperoxidase
(MPO) or control plasma (MPO) was immunoprecipitated with a poly-
clonal anti-myeloperoxidase antibody, and the proteins that were pulled
down were separated by SDS-PAGE under reducing conditions. The domi-
nant band (*) in the MPO lane with a molecular mass of 130 kDa was
identified as ceruloplasmin by mass spectrometry.
TABLE 1
Identification of ceruloplasmin
Underlined and boldface amino acids were identified in the immunoprecipitated
material isolated from the major band on the gel shown in Fig. 2F using mass
spectrometry. 541 amino acids of 1065 were identified, equating to 51% amino acid
sequence coverage.
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ceruloplasmin on the plate increased with increasing concen-
trations of myeloperoxidase (Fig. 4B). No ceruloplasmin was
detected in the absence of myeloperoxidase, and no signal was
observed in the absence of ceruloplasmin. These results suggest
that, whenmixed, myeloperoxidase and ceruloplasmin become
associated. The association must be largely reversible because
ceruloplasmin failed to saturate the plate, and it is likely that it
was dissociated from myeloperoxidase during the washing
steps unless it was present at very high concentrations.
We also used a polyclonal anti-myeloperoxidase antibody
to detect myeloperoxidase in the ELISA experiments just
described. The presence of ceruloplasmin did not affect the
signal for myeloperoxidase protein over a range of concentra-
tions (Fig. 4C). This result demonstrates that ceruloplasmin did
not affect either the binding or the detection of myeloperoxi-
dase on the ELISA plate. An intermediate step in the ELISA
allowsmyeloperoxidase activity to be determined bymeasuring
the hypobromous acid-dependent oxidation of Amplex Red
(Fig. 4D). When ceruloplasmin was incubated with myeloper-
oxidase at a 1000-fold excess (open circles), enzyme activity was
inhibited by70% comparedwith thatmeasured formyeloper-
oxidase alone (closed circles). Thus, binding of ceruloplasmin to
myeloperoxidase inhibits the halogenation activity.
Ceruloplasmin Inhibits the Enzymatic Activities of Myelo-
peroxidase—Next we investigated the mechanism by which
ceruloplasmin inhibits the production of hypochlorous acid by
myeloperoxidase. Initially we used an assay that has previously
been used to test whether ceruloplasmin inhibits the chlorina-
tion activity of myeloperoxidase (24, 36). In this assay,
myeloperoxidase and chloride are incubated with taurine, and
the concentration of accumulated taurine chloramine formed
is determined when about half of the added hydrogen peroxide
has been consumed. A 5-fold excess of ceruloplasmin inhibited
myeloperoxidase-dependent production of hypochlorous acid
by 9–49% with a mean and S.E. of 30  3% (n  12). These
results are in accord with previous studies in which ceruloplas-
min was found to inhibit accumulation of taurine chloramine
by 40–60% (24, 36). When urate (100 M) was added to the
reaction system to ensure that the enzyme could cycle via Com-
pound II (37, 38), the inhibitory effect of ceruloplasmin
increased to 56 10% (n 3).
To gain a better appreciation of how effective ceruloplasmin
is as an inhibitor of myeloperoxidase, the initial rates of hypo-
chlorous acid were measured in continuous assays. These
included the oxidation of ascorbate (31) and the chlorination of
NADH (32). Ascorbate can be oxidized either by reaction with
hypochlorous acid (39) or by the peroxidation cycle involving
Compound I and Compound II (40). In the presence of 140mM
FIGURE 3. Association of purified myeloperoxidase and ceruloplasmin.
Myeloperoxidase (30g, 6.8M) wasmixed with either 30g (3.9M) (A), 60
g (7.8M) (B), or 150g (19.5M) (C) of ceruloplasmin at room temperature
in PBS for 1 h prior to separation by size exclusion chromatography. The
proteins were detected at 430 nm formyeloperoxidase heme (black) and 610
nm for ceruloplasmin copper (gray).
FIGURE 4. Binding of ceruloplasmin inhibitsmyeloperoxidase. A, myeloper-
oxidase (8 nM) was incubated with increasing ratios of ceruloplasmin as
indicated for 1 h in PBS. Samples were applied to an ELISA plate coated with
an anti-myeloperoxidase monoclonal antibody, and ceruloplasmin was
detected using a polyclonal anti-ceruloplasmin antibody. B, detection of
ceruloplasmin after incubating the indicated concentrations ofmyeloperoxi-
dase either in the presence of a 1000-fold excess of ceruloplasmin (E) or in its
absence (F). Myeloperoxidase protein (C) or activity (D) was detected on the
ELISA plate after it had beenmixedwith (E) or without (F) a 1000-fold excess
of ceruloplasmin. Error bars, S.E.
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chloride, ascorbate was oxidized predominantly via its reaction
with hypochlorous acid with a minor loss due to its direct oxi-
dation by the enzyme (Table 2). Ceruloplasmin inhibited the
oxidation of ascorbate, whereas the apoprotein did not (Fig. 5A
and Table 2). Ceruloplasmin alone did not oxidize ascorbate at
rates comparable with that for myeloperoxidase. Furthermore,
no inhibition was seen when ceruloplasmin was replaced with
human serum albumin.
Measurement of the initial rate of ascorbate oxidation was
used to determine the concentration of ceruloplasmin that
inhibited production of hypochlorous acid by 50% (IC50). At
concentrations of myeloperoxidase of 20 and 40 nM/heme
group, the IC50 values for ceruloplasmin were 25 and 50 nM,
respectively (Fig. 5B). Maximal inhibition occurred with 2
mol of ceruloplasmin/heme. These results indicate that cerulo-
plasmin is a potent inhibitor of myeloperoxidase.
To assess how ceruloplasmin inhibits oxidation of halides by
myeloperoxidase, its effect on the initial rate of ascorbate oxi-
dation was assessed at varying concentrations of chloride or
bromide. The initial rate of ascorbate oxidation increased with
increasing concentrations of chloride and bromide up to amax-
imum (Fig. 5, C and D). Kinetic constants for the halides were
obtained from such curves and are shown in Table 3. These
constants were kcat/Km and kcat (Vmax/[myeloperoxidase]),
which define the rate at which enzymes capture their substrates
into productive complexes and release their products (41, 42).
Incubation ofmyeloperoxidasewith ceruloplasmin lowered the
kcat for both halides by 50%. The ratio kcat/Km was also
decreased in the presence of ceruloplasmin. This pattern of
inhibition is typical of a mixed type inhibitor (42) (i.e. cerulo-
plasmin displays properties of both a competitive and uncom-
petitive inhibitorwith respect to halides). It indicates that in the
presence of ceruloplasmin the rate-determining step in turn-
over of myeloperoxidase must change so that it is much less
dependent on the concentration of halide than in the absence of
ceruloplasmin.
To determine how ceruloplasmin affected the kinetic con-
stants for hydrogen peroxide, we used a more sensitive assay
that monitors the chlorination of NADH to produce a chloro-
hydrin with a distinctive absorption spectrum (43). The initial
rate of chlorohydrin formation increased to a maximum with
increasing concentrations of hydrogen peroxide (Fig. 5E).
Ceruloplasmin dramatically affected the initial rate of chloro-
hydrin formation and caused a 75% reduction in kcat but had
little effect on kcat/Km (Table 3). This pattern of inhibition is
typical of an uncompetitive inhibitor and suggests that cerulo-
plasmin does not compete directly with hydrogen peroxide for
reaction with myeloperoxidase.
We also determined whether ceruloplasmin affects the per-
oxidation activity ofmyeloperoxidase bymeasuring its effect on
the oxidation of serotonin. Serotonin is the best physiological
substrate for the enzyme, reacting rapidlywith bothCompound
TABLE 2
Oxidation of ascorbate by myeloperoxidase
The oxidation of ascorbate (100 M) by myeloperoxidase (MPO; 20 nM) was mon-
itored over time in the presence and absence of ceruloplasmin (Cp; 100 nM). Reac-
tions containing Clwere performed in PBS, and those without Clwere in 50 mM
phosphate buffer, pH 7.4. Reactions were started by the addition of hydrogen per-
oxide (50 M). Rates were measured over the first 30 s of the reaction. Data are the
mean and S.E. of n experiments.
Sample ( 100 M ascorbate) Rate of ascorbate oxidation
M/s
MPO H2O2 Cl 0.60 0.03 (n 23)
MPO H2O2 0.08 0.01 (n 4)
H2O2 0.02 0.01 (n 4)
CpMPO H2O2 Cl 0.30 0.02 (n 17)
ApoCpMPO H2O2 Cl 0.86 0.03 (n 5)
CpMPO H2O2 0.10 0.04 (n 6)
Cp H2O2 0.09 0.04 (n 4)
MPO HSA H2O2 Cl 0.68 0.13 (n 5)
FIGURE 5. Steady state kinetics of the inhibition of myeloperoxidase by
ceruloplasmin. A, the rate of hypochlorous acid productionwas determined
by monitoring the oxidation of ascorbate at 265 nm. Myeloperoxidase alone
(20 nM) (solid line), ormyeloperoxidase preincubatedwith ceruloplasmin (100
nM) (dashed line) or human serumalbumin (100 nM) (dotted line) was added to
a solution of ascorbate (100 M) in PBS. B, myeloperoxidase (20 nM (F) or 40
nM (Œ)) was incubated with increasing concentrations of ceruloplasmin (25–
150 nM) for 30 min prior to measurement of the initial rate of ascorbate oxi-
dation. C, myeloperoxidase (20 nM) was incubated in phosphate buffer, pH
7.4, and 0–140 mM chloride, in the presence (100 nM (E) or 20 nM (‚)) and
absence (F) of ceruloplasmin for 1 h at room temperature prior to measure-
ment of the initial rate of ascorbate oxidation. D, myeloperoxidase (20 nM)
was incubated in phosphate buffer, pH 7.4, and 0–5mMbromide, in the pres-
ence of either 40 nM (‚) or 120 nM (E) ceruloplasmin, as well as in its absence
(F) for 1 h at room temperature prior to measurement of the initial rate of
ascorbate oxidation. E, myeloperoxidase (20 nM) was incubated with NADH
(100M) in PBS in thepresence (E) and absenceof ceruloplasmin (100nM) (F)
for 1 h at room temperature. The initial rate of NADH chlorohydrin formation
was monitored at 275 nm. F, myeloperoxidase (10 nM) was incubated with
0–1mM serotonin in the presence (E) and absence of ceruloplasmin (100 nM)
(F) in phosphate buffer, pH 7.4, for 1 h at room temperature. Serotonin dimer
formation was monitored at 317 nm over the first 30 s of the reaction. All
reactions were started by the addition of 50M hydrogen peroxide except as
indicated in E. Rate data are the mean and ranges (error bars) of duplicate
measures and are representative of two or more experiments.
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I (k 1.7 107 M1 s1) and Compound II (k 1.4 106 M1
s1) (44). The rate of oxidation of serotonin was determined by
measuring the formation of the serotonin dimer. The rate of
this reaction is determined by how fast serotonin reacts with
Compound II (34). Ceruloplasmin was an excellent inhibitor of
serotonin oxidation (Fig. 5F). It substantially decreased the
kcat/Km but had a lesser effect on kcat. This pattern is typical of a
competitive inhibitor. It suggests that ceruloplasmin slows the
rate at which serotonin can reduce Compound II.
Ceruloplasmin Reduces Compound I to Compound II—The
steady state data provided insight into the mechanism of inhi-
bition of myeloperoxidase, but additional evidence was
required to establish the reactions responsible for preventing
production of hypochlorous acid. We used stopped flow kinet-
ics to determine whether ceruloplasmin affects the formation
and decay of Compound I.When ferricmyeloperoxidase reacts
with hydrogen peroxide, it forms Compound I with a second
order rate constant of 1.8  107 M1 s1 (45). Thus, when
myeloperoxidase (1.0M) and hydrogen peroxide (10M) were
mixed, Compound Iwas formed in40ms. This formationwas
observed as a decrease in absorption at 430 nmdue to the lower
extinction coefficient of Compound I at this wavelength com-
pared with the ferric enzyme (Fig. 6A) (45). In contrast, in the
presence of one molecule of ceruloplasmin per heme group of
myeloperoxidase, a decrease in absorption at 430 nm was still
observed, but there was a concomitant increase at 456 nm that
is associated with formation of Compound II (Fig. 6B).
The high rate of the initial reaction of hydrogen peroxide
with ferric enzyme means that this reaction can be followed
kinetically only by a series of single wavelength experiments at
430 and 456 nm using a photomultiplier. When myeloperoxi-
dase alone reacted with hydrogen peroxide, there was an expo-
nential decrease in absorption at 430 nm and little absorption
change at 456 nm (Fig. 6C). This shows that only Compound I
was formed during this short time period of 100 ms. Preincu-
bation of myeloperoxidase with ceruloplasmin decreased the
rate of loss of absorption at 430 nm but promoted a rapid
increase in absorption at 456 nm (Fig. 6C). Thus, ceruloplasmin
promotes fast reduction of Compound I to Compound II.
When the reaction was followed over longer periods (0–500
s), Compound I decayed into Compound II through reaction
with hydrogen peroxide (46). This reaction can be followed at
456 nm, where Compound II accumulates over20 s, and the
apparent second order rate constant we obtained was 6.9 104
M1 s1, which is well within the range of values previously
reported (47). In comparison, ceruloplasmin increased this rate
by a factor of 10, with maximum Compound II accumulating
within 2 s. Compound II then decayed back to ferric myeloper-
oxidase slowly over 400 s. Similar rates of decay were
observed in the absence and presence of ceruloplasmin (data
not shown).
Ceruloplasmin Inhibits Reduction of Compound II—Next we
used the stopped flow technique to determine how ceruloplas-
min affects the reduction of Compound II by a classical perox-
idase substrate. Due to its stability and well characterized reac-
TABLE 3
Kinetic parameters for the oxidation of halides and bymyeloperoxidase in the presence and absence of ceruloplasmin
Values were determined by fitting rectangular hyperbola to the results presented in Fig. 5. Cp, ceruloplasmin; kcat, Vmax/	myeloperoxidase
. Data for chloride and bromide
were obtained in the ascorbate assay, whereas data for hydrogen peroxidewere in theNADHassaywith chloride at 140mM. The ratios of ceruloplasmin tomyeloperoxidase
were 1:1 for chloride and 2:1 for bromide.
Substrate
kcat Km kcat/Km
Cp Cp Cp Cp Cp Cp
s1 mM mM1 s1
Chloride 50 27 42.1 152 1190 178
Bromide 115 75 2.1 2.5 5.5 104 3.0 104
H2O2 15 3.5 0.02 0.004 7.5 105 9.7 105
FIGURE 6. Stopped flow spectral and kinetic observations of the initial
reaction betweenmyeloperoxidase and hydrogen peroxide in the pres-
ence and absence of ceruloplasmin.A, spectral changes aftermyeloperoxi-
dase (1.0 M/heme final) was reacted with hydrogen peroxide (10 M final).
Scans were recorded at 3 ms (thick black line), 7 ms, 10 ms, 25 ms, 50 ms, and
100ms (thick gray line). B, same as A, but myeloperoxidase was preincubated
with ceruloplasmin (1 M final). The ceruloplasmin spectrum has been
removed from each time trace. C, single wavelength kinetic traces measured
under the same conditions as in A (solid lines) and B (dotted lines) followed by
thephotomultiplier at 430nm(black lines) and456nm(gray line). Thedata are
representative of at least two experiments.
Ceruloplasmin Inhibits Myeloperoxidase
6472 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 9•MARCH 1, 2013
 by guest on Septem
ber 17, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
tions, tyrosine was used as the reducing substrate (46, 48).
Myeloperoxidase in the absence or presence of one ceruloplas-
min per heme group was premixed with hydrogen peroxide for
20 and 2 s, respectively, to ensuremaximum formation of Com-
pound II. The resultant mixture was then mixed with tyrosine
(200 M final), and the absorption changes were followed. In
the absence of ceruloplasmin, Compound IIwas fully converted
back to ferric myeloperoxidase by tyrosine (Fig. 7A). By follow-
ing absorption at 456 nm (Fig. 7C), a first order rate constant of
3.6 s1 was obtained. This corresponds to an apparent second
order rate constant of 1.8 104 M1 s1, similar to that previ-
ously published (46). When ceruloplasmin was preincubated
with myeloperoxidase, a much smaller decrease in the amount
of Compound II was observed (Fig. 7B). However, the absorp-
tion at 456 nm decreased with a similar first order rate of 3.8
s1. The loss of absorbance at 456 nmover a longer time scale of
80 s (Fig. 7C, inset) decreased with a first order rate constant of
0.04 s1 comparedwith 0.007 s1 for the decay of Compound II
(Fig. 6C). The former value most likely refers to the first order
dissociation of a complex between myeloperoxidase and
ceruloplasmin.
Ceruloplasmin Converts Myeloperoxidase to Compound II in
the Presence of Chloride—The high rate of Compound II forma-
tion in the presence of ceruloplasmin means that it was not
possible to follow the reaction of Compound I with chloride
when this protein is present. Therefore, to demonstrate how
ceruloplasmin affects the turnover of myeloperoxidase in the
presence of chloride, we monitored the Soret spectrum before
and after the addition of hydrogen peroxide. In the absence of
ceruloplasmin, there was partial and transient conversion of
myeloperoxidase to Compound II upon the addition of hydro-
gen peroxide, as noticed by a shift in the Soret peak from 430 to
FIGURE 8. The influence of ceruloplasmin on the formation of the redox
intermediates of myeloperoxidase. A, spectra of myeloperoxidase (1
M/heme)were recorded in PBS before (solid line), 10 s (dotted line), and 120 s
(dashed line) after the addition of hydrogen peroxide (100M). Methionine (1
mM) was added to scavenge hypochlorous acid. B, as in A, but myeloperoxi-
dase was preincubated with ceruloplasmin (10 M) for 1 h. C, as in A, but
myeloperoxidase was preincubated with human serum albumin (10 M) for
1 h. The spectrophotometer was blanked against PBS.
FIGURE 7. Stopped flow spectral and kinetic observations of the reaction
betweenCompound II and tyrosine in thepresence andabsence of ceru-
loplasmin. A, spectral changes after myeloperoxidase (1.0 M/heme final)
was mixed with hydrogen peroxide (10 M final) and incubated for 20 s to
produceCompound II before reactionwith tyrosine (200M final). Scanswere
then recorded at 1ms (thick black line), 10ms, 50ms, 100ms, 250ms, 500ms,
and 3 s (thick gray line). The arrows indicate direction of spectral changes.
B, sameasAbut included ceruloplasmin (1M final) andonly incubated for 2 s
before reaction with tyrosine. The ceruloplasmin spectrum has been
removed fromeach time trace.C, single kineticwavelength tracemeasuredat
456 nm under the same conditions as A (bottom; kobs  3.6 s
1) and B (top;
kobs  3.8 s
1). The inset shows the reaction of B over a longer time scale
(0–80 s), indicating a second slower exponential decrease (kobs 0.04 s
1).
Representative data are shown, and the observed rate constants are the aver-
age of at least two experiments.
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456 nm and the appearance of a small band at 630 nm (Fig. 8A).
The enzyme completely reverted to the native state (Soret peak
at 430 nm) after 2.5 min. Incubation of myeloperoxidase with
ceruloplasmin resulted in amarked spectral shift after the addi-
tion of hydrogen peroxide, consistent with the generation of
Compound II (49) (Fig. 8B). Compound II was stable for at least
2min, and the ferric enzyme regenerated slowly over 8min (not
shown). In contrast, incubating myeloperoxidase with human
serum albumin resulted in only a temporary generation of
Compound II after adding hydrogen peroxide (Fig. 8C). From
these results we conclude that ceruloplasmin competes with
chloride to promote the accumulation of Compound II and
slows its subsequent conversion back to the native enzyme.
DISCUSSION
Our finding that a deficiency of ceruloplasmin in plasma
leads to enhanced oxidation of ascorbate by myeloperoxidase
demonstrates that this copper-containing protein is an impor-
tant endogenous inhibitor of myeloperoxidase. During inflam-
mation, ceruloplasmin should act as an antioxidant by limiting
myeloperoxidase-dependent production of reactive oxygen
species. To support this conclusion, we found that ceruloplas-
min is an exceptional inhibitor of myeloperoxidase, having a
much lower IC50 than the best known inhibitors of the enzyme
(50, 51). Our evidence supports a mechanism whereby the pro-
teins become associated with each other and then ceruloplas-
min reduces Compound I to Compound II as well as retards
subsequent reduction of Compound II back to active
myeloperoxidase.
We found that when a large concentration of myeloperoxi-
dase was added to plasma, about one-third became associated
with plasma proteins, which reversibly inhibited its activity.
Our immunoprecipitation experiments support the finding of
an earlier study that ceruloplasmin is the major protein in
plasma that becomes associated with myeloperoxidase (20).
Complement C3 also co-purified with myeloperoxidase. No
other proteins were observed as specific binding partners of the
enzyme. Previously, interactions betweenmyeloperoxidase and
lipoproteins in vitro and in plasma have been demonstrated
(52–54). Compared with ceruloplasmin, these other proteins
are likely to form minor associations with myeloperoxidase, as
suggested recently (36).
Our experiments using size exclusion chromatography with
SDS-PAGE analysis and ELISA confirm that myeloperoxidase
and ceruloplasmin readily associate in a largely reversible man-
ner. The results of size exclusion chromatography suggest that
the stoichiometry of binding is 2 ceruloplasminmolecules/mol-
ecule of myeloperoxidase. Using photon correlation spectros-
copy, Sokolov et al. (55) showed evidence for the binding of the
two proteins at this ratio. Electrostatic interactions between
anionic charges on ceruloplasmin and cationic residues on
myeloperoxidase have been proposed as the mechanism of
binding between the two proteins (20). The binding of cerulo-
plasmin to protein C and ferritin involves an anionic region on
ceruloplasmin (amino acids 1028–1037) (56). Ceruloplasmin
also binds to lactoferrin, and the cationic region 2RRRR5 on
lactoferrin is a likely binding site. A similar sequence in
myeloperoxidase, 374KRKGR378, may be the site where cerulo-
plasmin attaches to the enzyme (57). However, we consistently
saw inhibition of myeloperoxidase in the presence of the ani-
onic detergent CETAC, suggesting that the interaction is
unlikely to be solely electrostatic.
The reactions myeloperoxidase undergoes to oxidize chlo-
ride and organic substrates to reactive species are shown in Fig.
9A. On the basis of our current evidence, the mechanism of
inhibition of these reactions requires the initial reversible bind-
ing of ceruloplasmin to each monomer of myeloperoxidase
(Fig. 9B). Steady state as well as fast kinetic data indicate that
this complex still reacts rapidly with hydrogen peroxide to form
Compound I. It was apparent from stopped flow experiments
that ceruloplasmin then readily reduces Compound I to Com-
pound II (Fig. 9C). This reaction explains how ceruloplasmin
converted myeloperoxidase to Compound II in the presence of
chloride. Inhibition is caused not only by reduction of theCom-
pound I but also by the ability of ceruloplasmin to prevent the
recycling of Compound II back to the active enzyme. The latter
aspect of inhibition was apparent in the stopped flow experi-
ments, whereby the association of ceruloplasmin was shown to
FIGURE 9. Reactions of myeloperoxidase in the presence and absence of
ceruloplasmin.A, ferricmyeloperoxidase (MPO) reactswithhydrogenperox-
ide to form the redox intermediate Compound I, which either oxidizes chlo-
ride by removing two electrons or removes a single electron from an organic
substrate (RH), such as urate, ascorbate, tyrosine, or serotonin, to produce an
organic radical (R) and Compound II. Compound II is also reduced by these
substrates to produce a second radical and regenerate ferric MPO. Only a
singlemonomer ofmyeloperoxidase is illustrated. B, amolecule ofmyeloper-
oxidase (MPO) consisting of two identical dimers, each containing a heme
prosthetic group, binds reversibly to two molecules of ceruloplasmin (CP).
C, reaction of hydrogenperoxidewithmyeloperoxidase bound to ceruloplas-
min enhances the one-electron reduction of Compound I to Compound II.
Reduction of Compound II is slowed until it dissociates from ceruloplasmin.
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dramatically slow the reduction of Compound II by tyrosine. It
was also apparent from the ability of ceruloplasmin to retard
the steady state oxidation of serotonin. The demonstration that
ceruloplasmin was more effective at inhibiting myeloperoxi-
dase in the presence of reducing substrates, such as urate,
ascorbate, and NADH, suggests that its ability to slow the turn-
over of Compound II is an important component of its mecha-
nism of inhibition. Reduction of Compound I and then retar-
dation of the turnover of Compound II fits squarely with the
mixed inhibition pattern we observed when the concentration
of halides was varied at differing concentrations of ceruloplas-
min. The dissociation of ceruloplasmin from Compound II
would then determine the rate of turnover of myeloperoxidase
and consequently its chlorination activity.
Themechanismwe have described has several essential attri-
butes for an endogenous inhibitor of myeloperoxidase. First,
ceruloplasmin inhibits well below its normal plasma concentra-
tion, it impedes both the production of hypohalous acids and
reactive free radicals, and by binding to myeloperoxidase it
should limit interactions with other susceptible proteins,
including those on the endothelium. Themechanism of inhibi-
tion is similar to the action of several nonsteriodal anti-inflam-
matory drugs and halogenated indoles that inhibit myeloper-
oxidase by promoting the accumulation of Compound II (38,
58). However, these inhibitors are not as effective as ceruloplas-
min because they do not impair subsequent reduction of Com-
pound II back to the active enzyme. The ability of ceruloplas-
min to essentially trap myeloperoxidase in its Compound II
redox state means that the enzyme’s activities will decline to a
rate determined by the dissociation of the two proteins. Conse-
quently, in vivo the decreased rate of hydrogen peroxide con-
sumption by myeloperoxidase will allow endogenous scaven-
gers of hydrogen peroxide to compete more effectively with
myeloperoxidase and further limit oxidant production.
The interactions between ceruloplasmin and myeloperoxi-
dase are intriguing. It will of interest to learn how ceruloplas-
min binds to myeloperoxidase so that it can reduce Compound
I and prevent substrates from reducing Compound II. This will
require a detailed knowledge of electron transfer between the
proteins, whether this is an enzymatic process with respect to
ceruloplasmin, and the absolute kinetics of each step.
At sites of inflammation where myeloperoxidase is dis-
charged from activated neutrophils (2, 57, 59), the likelihood
of it encountering ceruloplasmin is high because cerulo-
plasmin is an abundant acute phase plasma protein present
at concentrations of 2–4 M (60). Indeed, complexes of
myeloperoxidase and ceruloplasmin have been seen in plasma
and serum from patients suffering from inflammatory condi-
tions (36). In contrast, ceruloplasmin would not be expected to
inhibit myeloperoxidase during bacterial killing by neutrophils
because it would have limited access to phagosomes (3).
Ceruloplasmin is a multicopper oxidase that contains 90% of
the copper in plasma. Aceruloplasminemia is a rare autosomal
recessive disease that results in iron accumulation in the pan-
creas, liver, and brain, and patients suffer from diabetes and
neurodegeneration (61). This abnormality suggests that the
most important function of ceruloplasmin is its ferroxidase
activity, where reactive Fe2 is oxidized to Fe3, providing Fe3
for transferrin and preventing Fe2 from participating in the
generation of hydroxyl radicals (62). Ceruloplasmin has both
pro-oxidant and anti-oxidant properties and has been
described as a “moonlighting protein” due to its many and var-
ied activities (63). These also include amine oxidase (25), nitric-
oxide oxidase (27), and glutathione peroxidase activities (64).
Inhibition ofmyeloperoxidase should be added to this list but is
likely to be a minor function of ceruloplasmin because a small
proportion only of circulating ceruloplasmin is required to
attenuate oxidant production by myeloperoxidase. In the
future it will be of interest to determine whether these other
activities of ceruloplasmin impinge on its ability to inhibit
myeloperoxidase and thereby promote oxidative stress.
Elevated levels of ceruloplasmin have been reported in many
cardiovascular disorders and correlate with cardiovascular risk
(65, 66). Ceruloplasmin is capable of oxidizing LDL (67), and it
has been hypothesized that oxidized LDL is involved in the
progression of atherosclerosis (68). There is also much evi-
dence that myeloperoxidase has a role in the development of
heart disease (6, 69, 70), suggesting a complex redox environ-
ment where ceruloplasmin can limit myeloperoxidase activity
at sites of inflammation but also contribute to oxidative
damage.
In summary, we have shown that ceruloplasmin is a potent
endogenous inhibitor of myeloperoxidase. However, when
ceruloplasmin is overwhelmed by myeloperoxidase, as may
occur in sepsis (71) or within the airways of children with cystic
fibrosis (8), then it may be free to produce reactive oxygen
species. Recently, increased mortality and a greater degree of
protein oxidation were seen in Cp/ mice in a model of
inflammatory bowel disease compared with controls (72).
Unrestricted activity of myeloperoxidase may have been
responsible for this oxidation. This possibility warrants closer
scrutiny because neutrophils are major inflammatory cells in
this disease, releasing large amounts of myeloperoxidase into
the intestinal mucosa (73). Alternatively, the balance between
ceruloplasmin and myeloperoxidase may be tipped to a pro-
oxidant state by antibodies to myeloperoxidase that occur in
antineutrophil cytoplasmic autoantibody-mediated vasculitis
(74). Some of these antibodies have been shown to prevent
ceruloplasmin from binding to and inhibiting myeloperoxidase
(22). Consequently, further investigation of the interplay
between ceruloplasmin and myeloperoxidase will allow a
greater understanding of how oxidative stress manifests during
inflammation.
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